BUSINESS NEWS
Aastrom Biosciences Reports Positive Bone Repair Results in Clinical Feasibility Trial
Aastrom Biosciences, Inc. announced today the results from its feasibility clinical trial conducted with the Institut de Terapia Regenerativa Tisular (ITRT) in Barcelona, Spain to evaluate the use of Aastrom’s Tissue Repair Cells (TRCs) for the treatment of severe long bone non-union fractures.
Article
Australian Patent Granted for Norwood Immunology
Norwood’s immunology technology is based on the use of U.S. Food and Drug Administration (FDA)-approved GnRH analogue drugs to regenerate the thymus gland and enhance bone marrow function.
Article
Asklepios Biopharmaceutical, Inc. and Bayer Healthcare, LLC Announce Collaboration on Gene Therapy for the Treatment of Hemophilia
Bayer HealthCare, LLC, Biological Products Division (Bayer BP), and Asklepios Biopharmaceutical Inc. (AskBio), a private development-stage biotechnology company, announced today they have entered into an early-stage research and collaboration agreement to evaluate gene therapy for the treatment of hemophilia B.
Article
Cell Genesys, Inc. Receives Special Protocol Assessment From FDA For Second Phase 3 Trial Of GVAX(R) Vaccine For Prostate Cancer
Article
Corautus Genetics Inc. Enters Into Long Term Manufacturing Agreement With Boehringer Ingelheim Austria GmbH For Production Of VEGF-2 Plasmid DNA
Corautus Genetics Inc. and Boehringer Ingelheim Austria GmbH announced today that they have entered into a long term manufacturing agreement to produce VEGF-2 (Vascular Endothelial Growth Factor 2) plasmid DNA for a Phase III trial and future commercial use for the treatment of cardiovascular disease (severe angina) and other indications.
Article
CytoGenix Launches Innovative Vaccine Program Using Proprietary Cell-Free DNA Production Process
CytoGenix, Inc. announced today that it has begun an accelerated program to develop DNA vaccines against several diseases including influenza.
Article
InNexus Teams with Mayo Clinic to Develop Antibodies
InNexus Biotechnology, Inc. today announced a multi-year collaborative research agreement with Mayo Clinic aimed at advancing the leading science of monoclonal antibody development, and for the creation of promising new medicines for cancer, cardiovascular disease and other difficult-to-treat diseases.
Article
Invitrogen to Acquire Immunological Reagent Provider Caltag Laboratories; Deal Adds Expertise in Assays for Flow Cytometry to Strengthen Invitrogen’s Growing Proteomics Portfolio
Invitrogen Corporation today announced it has signed a definitive agreement to acquire privately held immunological assay manufacturer Caltag Laboratories in a cash transaction totaling $20 million.
Article
Takara Bio to Introduce ViroMed’s Proprietary Gene Therapy Vector
Takara Bio announced on May 13 that it has concluded a licensing agreement with ViroMed, one of its consolidated subsidiaries in Korea specializing in gene therapy.
Article
Results of EGF Specific Active Immunotherapy in Patients With Advanced Non-Small-Cell Lung Cancer Presented at ASCO Annual Meeting
CancerVax Corporation announced today that data from a Phase 2 clinical trial showed that treatment with SAI-EGF, a specific active immunotherapy product candidate that targets the epidermal growth factor (EGF) receptor signaling pathway, was well tolerated, stimulated an antibody response to EGF, and reduced circulating EGF in patients with advanced non-small-cell lung cancer.
Article
MARKET REPORTS
Malachite Management has joined forces with established and reputable authors and publishers to bring you the following market reports outlining the very latest in Cell Therapy, Gene Therapy, and Immunotherapeutic approaches to Cancer.
“Cell Therapy – Technologies, Markets, and Companies” is over 400 pages of the basic technologies, clinical applications, market analysis, and company profiles related to the cell therapy industry worldwide.
For more information, including order forms, please see:
Cell Therapy Report Summary
Cell Therapy Sample Chapter
Cell Therapy Table of Contents Vol. 1 Vol. 2
Cell Therapy Order Form
“Gene Therapy – Technologies, Markets, and Companies” is over 500 pages of the basic technologies, clinical applications, market analysis, and company profiles related to the gene therapy industry worldwide.
For more information, including order forms, please see:
Gene Therapy Report Summary
Gene Therapy Table of Contents Vol. 1 Vol. 2
Gene Therapy Order Form
The Immunotherapy Reports cover the most recent developments in the immunotherapeutic approaches to cancer.
A Shift in Cancer Immunotherapy Strategies?
Immunotherapy Strategies Executive Summary
Immunotherapy Strategies Table of Contents
Future Perspectives in Cancer Immunotherapy
Future Perspectives Executive Summary
Future Perspectives Table of Contents
Immunotherapy Reports Order Form